Table 1 Histologic and clinical characteristics of non-small cell lung cancer patients tested in this study
From: EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
| Â | Adenocarcinoma | Squamous | Others a | Total |
|---|---|---|---|---|
Total cases | 1820 | 290 | 206 | 2316 |
 Median age | 60(26–92) | 62(30–88) | 60(12–83) | 61(12–92) |
 Sex, M/F | 917/903 | 247/43 | 144/62 | 1308/1008 |
EGFR mutant cases | 1021 | 11 | 63 | 1095 |
 Frequency in total | 56.1% | 3.8% | 30.6% | 47.3% |
 Median age | 60(26–86) | 64(38–89) | 57(27–74) | 60(26–89) |
 Sex, M/F | 397/624 | 5/6 | 28/35 | 430/665 |
EGFRex20ins cases | 49 | 0 | 4 | 53 |
 Frequency in EGFR mutant | 4.8% | 0 | 6.3% | 4.8% |
 Frequency in total | 2.7% | 0 | 1.9% | 2.3% |
 Median age | 57(31–85) | – | 56.5(49–70) | 57(31–85) |
 Sex, M/F | 26/23 | – | 2/2 | 28/25 |